Bulletin
Investor Alert

EyePoint Pharmaceuticals Inc.

NAS: EYPT

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
EyePoint Pharmaceuticals Inc.

After Hours

 --Quotes are delayed by 20 min

Mar 28, 2023, 7:09 p.m.

EYPT
/zigman2/quotes/210537129/composite

$

2.90

Change

+0.05 +1.75%

Volume

Volume 1,457

Quotes are delayed by 20 min

/zigman2/quotes/210537129/composite

Today's close

$ 2.83

$ 2.85

Change

+0.02 +0.71%

Day low

Day high

$2.72

$3.02

Open

52 week low

52 week high

$2.19

$13.05

Open

Company Description

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The...

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Valuation

Price to Sales Ratio

3.15

Price to Book Ratio

1.24

Enterprise Value to EBITDA

0.26

Enterprise Value to Sales

-0.48

Total Debt to Enterprise Value

1.43

Efficiency

Revenue/Employee

287,528.00

Income Per Employee

-710,097.00

Receivables Turnover

2.45

Total Asset Turnover

0.19

Liquidity

Current Ratio

5.00

Quick Ratio

4.92

Cash Ratio

4.19

Profitability

Gross Margin

74.94

Operating Margin

-190.65

Pretax Margin

-246.97

Net Margin

-246.97

Return on Assets

-46.09

Return on Equity

-72.84

Return on Total Capital

-43.10

Return on Invested Capital

-57.69

Capital Structure

Total Debt to Total Equity

48.09

Total Debt to Total Capital

32.48

Total Debt to Total Assets

25.70

Long-Term Debt to Equity

36.62

Long-Term Debt to Total Capital

24.73

Officers and Executives

Name Age Officer Since Title
Dr. Jay S. Duker 63 2016 Chief Strategic Scientific Officer
Mr. George O. Elston 56 2019 CFO & Head-Corporate Development
Dr. Said Saim 61 2019 Chief Technology Officer
Dr. Dario A. Paggiarino 62 2016 Chief Medical Officer & Senior Vice President
Ms. Jennifer Leonard - - Chief People Officer & Senior Vice President-IT

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
09/04/2020 George O. Elston
Chief Financial Officer 		10,000   Acquisition at $0.48 per share. 4,800
08/24/2020 George O. Elston
Chief Financial Officer 		10,000   Acquisition at $0.61 per share. 6,100
06/30/2020 Nancy Sue Lurker
President & CEO; Director 		124,667   Derivative/Non-derivative trans. at $0 per share. 0
06/30/2020 Dario A. Paggiarino
Chief Medical Officer 		41,050   Derivative/Non-derivative trans. at $0 per share. 0
06/30/2020 Scott Jones
SVP & Chief Commercial Officer 		41,050   Derivative/Non-derivative trans. at $0 per share. 0
06/30/2020 Dario A. Paggiarino
Chief Medical Officer 		12,049   Derivative/Non-derivative trans. at $0.76 per share. 9,157
06/30/2020 Scott Jones
SVP & Chief Commercial Officer 		14,060   Derivative/Non-derivative trans. at $0.76 per share. 10,685
06/27/2020 Nancy Sue Lurker
President & CEO; Director 		40,000   Derivative/Non-derivative trans. at $0 per share. 0
06/27/2020 Dario A. Paggiarino
Chief Medical Officer 		10,000   Derivative/Non-derivative trans. at $0 per share. 0
06/27/2020 Dario A. Paggiarino
Chief Medical Officer 		2,936   Derivative/Non-derivative trans. at $0.79 per share. 2,319
06/14/2020 Nancy Sue Lurker
President & CEO; Director 		45,000   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2020 Dario A. Paggiarino
Chief Medical Officer 		14,200   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2020 Dario A. Paggiarino
Chief Medical Officer 		4,168   Derivative/Non-derivative trans. at $0.83 per share. 3,459
03/12/2020 George O. Elston
Chief Financial Officer 		10,000   Acquisition at $0.96 per share. 9,600
03/10/2020 Nancy Sue Lurker
President & CEO; Director 		98,000   Acquisition at $1.06 per share. 103,880
02/21/2020 Nancy Sue Lurker
President & CEO; Director 		137,174   Derivative/Non-derivative trans. at $0 per share. 0
11/15/2019 George O. Elston
Chief Financial Officer 		10,000   Acquisition at $1.43 per share. 14,300
10/12/2019 Nancy Sue Lurker
President & CEO; Director 		10,745   Derivative/Non-derivative trans. at $2.1 per share. 22,564
10/12/2019 Dario A. Paggiarino
Chief Medical Officer 		2,450   Derivative/Non-derivative trans. at $2.1 per share. 5,145
/news/latest/company/us/eypt

MarketWatch News on EYPT

  1. EyePoint Pharmaceuticals downgraded to neutral from buy at B. Riley FBR

    10:32 a.m. April 6, 2020

    - Tomi Kilgore

  2. EyePoint Pharmaceuticals stock price target cut to $4.00 from $5.75 at B. Riley FBR

    9:11 a.m. Sept. 24, 2019

    - Tomi Kilgore

  3. EyePoint Pharma shares jump on FDA approval of Yutiq implant

    7:38 a.m. Oct. 15, 2018

    - Ciara Linnane

  4. EyePoint Pharma shares surge 8% premarket as FDA approves Yutiq for uveitis

    7:31 a.m. Oct. 15, 2018

    - Ciara Linnane

  5. Charting the Market

    4:16 p.m. Jan. 5, 2016

    - Barron's Online

  6. PSivida shares skyrocket after drug meets trial goals

    12:41 p.m. Dec. 22, 2015

    - Emma Court

  7. PSivida's stock soars 41% in active premarket trade after positive trial results

    8:59 a.m. Dec. 22, 2015

    - Tomi Kilgore

  8. PSivida started at outperform with $6 stock price target at FBR & Co.

    8:36 a.m. Oct. 15, 2015

    - Tomi Kilgore

  9. FDA OKs pSivida uveitis drug for Phase III trials

    9:41 a.m. July 19, 2012

    - MarketWatch.com

  10. Monday’s biggest gaining and declining stocks

    6:30 p.m. Dec. 27, 2010

    - Kate Gibson

  11. Alimera, pSivida slammed by FDA move

    3:30 p.m. Dec. 27, 2010

    - Val Brickates Kennedy

  12. Alimera, pSivida crushed by FDA setback

    10:36 a.m. Dec. 27, 2010

    - Val Brickates Kennedy

  13. Alimera, pSivida, Bayer lead drug-stock rally

    1:15 p.m. Aug. 31, 2010

    - Val Brickates Kennedy

  14. Javelin rockets as drug stocks head south

    3:41 p.m. June 29, 2010

    - Val Brickates Kennedy

  15. Forest Labs falls, pSivida rallies

    1:21 p.m. April 8, 2010

    - Val Brickates Kennedy

  16. Stocks in the Spotlight Wednesday

    5:58 p.m. Dec. 23, 2009

    - Barron's Online

  17. Drug stocks sluggish; Achillion, pSivida rally

    2:33 p.m. Dec. 23, 2009

    - Val Brickates Kennedy

/news/nonmarketwatch/company/us/eypt

Other News on EYPT

  1. SVB Collapse Spurs Finance Executives to Re-Evaluate Cash Strategies

    5:32 a.m. March 16, 2023

    - The Wall Street Journal Interactive Edition

  2. 10-K: EYEPOINT PHARMACEUTICALS, INC.

    1:37 p.m. March 10, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  3. 10-Q: EYEPOINT PHARMACEUTICALS, INC.

    1:23 p.m. Nov. 4, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  7. Notable earnings before Wednesday's open

    10:24 a.m. Nov. 1, 2022

    - Seeking Alpha

  8. Repligen (RGEN) Q3 Earnings and Revenues Top Estimates

    8:45 a.m. Nov. 1, 2022

    - Zacks.com

  15. 10-Q: EYEPOINT PHARMACEUTICALS, INC.

    2:16 p.m. Aug. 5, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  19. Notable earnings before Wednesday's open

    10:48 a.m. Aug. 2, 2022

    - Seeking Alpha

  20. EyePoint reports preliminary Q2 net product revenue $11.3M

    1:46 p.m. July 18, 2022

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

EyePoint Pharmaceuticals, Inc.

480 Pleasant Street

Suite A-210

Watertown, Massachusetts 02472

Phone

1 6179265000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2023

View SEC Filings

Revenue

$41.40M

Net Income

$-102.25M

2022 Sales Growth

12.1%

Employees

144.00

Annual Report for EYPT

/news/pressrelease/company/us/eypt

Press Releases on EYPT

  2. EyePoint Shareholder Action Reminder

    7:32 p.m. March 21, 2023

    - Newsfile Corp

  4. EyePoint Shareholder Notice

    8:22 a.m. March 5, 2023

    - Newsfile Corp

  9. EyePoint Shareholder Action Reminder

    8:22 a.m. Feb. 26, 2023

    - Newsfile Corp

  11. EyePoint Shareholder Notice

    8:21 a.m. Feb. 19, 2023

    - Newsfile Corp

  13. EyePoint Shareholder Notice

    10:42 p.m. Feb. 14, 2023

    - Newsfile Corp

  14. EyePoint Shareholder Action Reminder

    8:33 p.m. Jan. 24, 2023

    - Newsfile Corp

  21. Loading more headlines...
Link to MarketWatch's Slice.